All articles
Evidence-led research on repurposed compounds and the protocols people actually ask about — cited to primary literature and reviewed for accuracy.
Curcumin Enhances Cisplatin in Breast Cancer Cells: Machine-Learned AgNOR Analysis (2026)
A 2026 in-vitro study on MCF-7 breast cancer cells evaluates curcumin plus cisplatin synergy using AgNOR staining and machine learning classification.
Metastatic Melanoma: ctDNA Drops Then Rises During Self-Directed Antiparasitic Use (Case Report 2026)
University of Florida oncologists publish a September 2026 case report of metastatic melanoma with initial ctDNA decline during self-directed ivermectin and fenbendazole use, followed by progression. Authors emphasize spontaneous regression as at least as plausible as drug effect.
Disulfiram Depletes PARPi-Resistant Dormant Cells in Ovarian Cancer
Preclinical study (Biomed Pharmacother, Sep 2026) shows disulfiram disrupts ALDH-mediated redox homeostasis to deplete PARPi-induced dormant reservoirs in high-grade serous ovarian cancer cell lines, durably suppressing clonogenic recovery. In-vitro evidence only; no human trial data.
Ivermectin Disrupts Stress Recovery in Neuroblastoma Cells
A new 2026 study from McGill University reveals how ivermectin inhibits stress granule clearance in neuroblastoma by blocking de novo Hsp70 synthesis — a novel mechanism that may inform ivermectin-based anticancer strategies.
Curcumin Solid Dispersion Boosts Chemotherapy Synergy in Lung Cancer Cells
A preclinical study shows curcumin formulated as a PVP K30 solid dispersion dramatically enhances solubility and synergizes with common chemotherapy drugs against lung cancer cells.
Curcumin-Loaded Nanocarrier Amplifies Ferroptotic Cell Death in Tumor Models via Autophagy Loop (2026)
A new curcumin-loaded nanocarrier uses glucose oxidase and an iron-copper metal-organic framework to create a self-amplifying autophagy-ferroptosis cycle that enhances tumor suppression in preclinical cell and animal models.
Curcumin and Baicalein Show Synergistic Chemopreventive Effects in Breast Cancer Rat Model
A new 2026 preclinical study in rats finds that curcumin and baicalein together significantly reduce mammary tumor burden, inflammation, and oxidative stress. The combination outperformed either compound alone, but human data is not yet available.
Curcumin Inhibits DNMT3B in Pancreatic Cancer: New 2026 Paper
New 2026 research demonstrates curcumins epigenetic mechanism against pancreatic cancer via DNMT3B inhibition, miR-29b restoration, and ROS-driven apoptosis.
Curcumin Curbs Colorectal Polyp Regrowth in 577-Patient RCT
A 577-patient randomized trial shows curcumin significantly suppresses growth of recurrent colorectal adenomas ≥6 mm after endoscopic polypectomy, with minimal side effects over 2 years.
Methylene Blue Hydrogel Achieves 95% Photodynamic Cell Kill in Gliosarcoma Preclinical Study (2026)
A 2026 study in Journal of Biomaterials Applications demonstrates a gelatin hydrogel loaded with methylene blue as a photodynamic therapy platform for gliosarcoma, achieving 95% cell death and 95.35% encapsulation efficiency.
Mebendazole and Flutamide Combination Shows Synergistic Antiproliferative Effects in Prostate Cancer Cell Lines (2026)
A new August 2026 in vitro study finds that combining mebendazole with flutamide produces synergistic antiproliferative effects in prostate cancer cell lines, reducing the required flutamide dose while increasing apoptosis. The evidence is entirely preclinical.
Curcumin Cuts Growth of Large Colorectal Adenomas in 577-Patient RCT
A Japanese multicenter RCT of 577 patients found that curcumin (180 mg twice daily) significantly suppressed the growth of recurrent colorectal adenomas over 2 years.
Nothing here yet.